HIV Testing & Womens Attitudes on HIV Vaccine Trials

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Gregory Zimet, Indiana University
ClinicalTrials.gov Identifier:
NCT00771537
First received: October 10, 2008
Last updated: June 28, 2013
Last verified: June 2013

October 10, 2008
June 28, 2013
November 2006
January 2011   (final data collection date for primary outcome measure)
  • Number of Participants Who Accepted Rapid HIV Testing. [ Time Frame: During study visit. At approximately 30 minutes into the study visit. After part 1 of the questionnaire was completed. ] [ Designated as safety issue: No ]
    Acceptance of rapid HIV testing. Acceptance was assessed by actual administration of rapid oral HIV test by research staff.
  • Willingness to Participate in a HIV Vaccine Clinical Trial [ Time Frame: Approximately 60 minutes into the study visit, at the end of Part 2 of the questionnaire. ] [ Designated as safety issue: No ]
    Willingness to Participate in a HIV Vaccine Clinical Trial. Assessed via participant self-report with 6 items on Part 2 of the questionnaire. Item responses measured on 5-point Likert-type scale ranging from Strongly Disagree (value = 1) to Strongly Agree (value = 5).
  • Acceptance of rapid HIV testing [ Time Frame: During study visit ] [ Designated as safety issue: No ]
  • Willingness to Participate in a HIV Vaccine Clinical Trial [ Time Frame: During Study Visit ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00771537 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
HIV Testing & Womens Attitudes on HIV Vaccine Trials
HIV Testing & Womens Attitudes on HIV Vaccine Trials

The purpose of this study is to test the effects of different persuasive informational messages on rates of rapid HIV testing and willingness to participate in a HIV vaccine clinical trial. Adult African-American, non-Latina White, and Latina women will be recruited. Women will initially be randomized to 4 groups: 1. no message control; 2. 1-sided message that mentions benefits of HIV testing; 3. 2-sided message that acknowledges minor opposition to testing, then refutes the opposition; and 4. 2-sided message that acknowledge stronger opposition to testing, then refutes the opposition. Women will be offered HIV testing, then re-randomized to a similar set of 4 messages related to HIV vaccine trials. There will therefore be 16 groups in total (4 X 4).

This 5-year proposal responds to PAS-03-168, "Enrolling Women and Minorities in HIV/AIDS Research Trials." This study seeks to evaluate persuasive message interventions to increase HIV testing rates and improve acceptability of participation in a phase 3 HIV vaccine clinical trial among African-American, Latina, and White women. We plan to evaluate 1-sided messages, which mention only the benefits of an action, versus 2-sided messages, which mention negative aspects of the action, followed by positive counterarguments. The Health Belief Model, Inoculation and Attribution Theories will guide the research. Participants will be women attending urban community health clinics in Indianapolis, IN. Specific Aim 1 is to identify obstacles to HIV testing and to participation in a HIV vaccine clinical trial. This aim will be accomplished in years 1 and 2 through individual semi-structured interviews. We will analyze data via thematic content analysis and will use interview findings to assist in the development of measures and interventions employed in the intervention phase (years 3-5). Specific Aim 2 is to evaluate the effects of 2-sided versus 1-sided persuasive messages on rates of acceptance of rapid HIV testing. Demographic, behavioral, and attitudinal measures will be administered via audio computer-assisted self-interview (A-CASI). Participants will be randomized to the intervention groups via A-CASI as well. The outcome will be acceptance/rejection of free rapid HIV testing. This Aim will be evaluated via binary logistic regression. Specific Aim 3 is to evaluate the effects of 2-sided versus 1-sided messages on willingness to participate in phase 3 clinical trials for a preventive HIV vaccine. Participants will complete this 2nd A-CASI survey and will again be randomized to intervention groups. The outcome will be a scale measuring acceptability of clinical trial participation. This Aim will be evaluated via one-way Analysis of Variance. This study is relevant to public health in that the results may help us to understand how to improve enrollment of women and minorities into preventive HIV vaccine clinical trials and how to encourage women and minorities to get tested for HIV.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
HIV
Behavioral: Message Sidedness
There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
  • No Intervention: Arm 1. Control PLUS Control
  • Experimental: Arm 2. Control PLUS 1-Sided
    No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 3. Control PLUS 2-Sided Trivial
    No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 4. Control PLUS 2-Sided Major
    No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 5. 1-Sided PLUS Control
    1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 6. 1-Sided PLUS 1-Sided
    1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 7. 1-Sided PLUS 2-Sided Trivial
    1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Aim 8. 1-Sided PLUS 2-Sided Major
    1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 9. 2-Sided Trivial PLUS Control
    2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 10. 2-Sided Trivial PLUS 1-Sided
    2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial
    2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 12. 2-Sided Trivial PLUS 2-Sided Major
    2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 13. 2-Sided Major PLUS Control
    2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 14. 2-Sided Major PLUS 1-Sided
    2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 15. 2-Sided Major PLUS 2-Sided Trivial
    2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
  • Experimental: Arm 16. 2-Sided Major PLUS 2-Sided Major
    2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
    Intervention: Behavioral: Message Sidedness
Burrage JW, Zimet GD, Cox DS, Cox AD, Mays RM, Fife RS, Fife KH. The Centers for Disease Control and Prevention revised recommendations for HIV testing: reactions of women attending community health clinics. J Assoc Nurses AIDS Care. 2008 Jan-Feb;19(1):66-74.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2031
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female
  • 18 years of age or older
  • Able to understand English or Spanish
  • Able to give informed consent

Exclusion Criteria:

  • Not female
  • Under 18 years of age
  • Not able to understand English and Spanish
  • Unable to give informed consent
Female
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00771537
0601-09, R01NR010004
Yes
Gregory Zimet, Indiana University
Indiana University
  • National Institutes of Health (NIH)
  • National Institute of Nursing Research (NINR)
Principal Investigator: Gregory D Zimet, PhD Indiana University
Indiana University
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP